Fluvoxamine treatment of major depression associated with multiple sclerosis.
Fluvoxamine 200 mg was administered for 3 months to a group of 43 interferon beta-1b treated patients affected by major depression associated with multiple sclerosis. Despite a 16.3% attrition rate, 79% of patients achieved response. The drug was well tolerated.
Benedetti
Francesco
F
Department of Neuropsychiatric Sciences, Università Vita-Salute San Raffaele, School of Medicine, Milan, Italy. benedetti.francesco@hsr.it
Campori
Euridice
E
Colombo
Cristina
C
Smeraldi
Enrico
E
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000209:etiology*; D004334:Drug Administration Schedule; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016666:Fluvoxamine; D000068576:Interferon beta-1b; D016899:Interferon-beta; D017367:Selective Serotonin Reuptake Inhibitors